OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Oncotelic Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.02+0.00 (+11.45%)
Close on Oct 19, 2026
- Market cap
- $8.66M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Share price
−$0.0810 (−81.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $8.66M
- P/E ratio
- 0.0
- Price to sales
- –
- Price to book
- 0.03
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- $249.30M
- EPS, diluted
- $0.59
- Book value per share
- $0.57
- Diluted shares
- 468M
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
–
Operating income
-$3.19M
Net income
$249.30M
EPS, diluted
$0.59
Free cash flow
–
Reported period